New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Can-Fite BioPharma Ltd.

Contributing Author

Recent Articles by Can-Fite BioPharma Ltd.

Feb-05	Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson CANF +5.20% GlobeNewswire
Jan-20	Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson CANF GlobeNewswire
Dec-26	Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction CANF +18.64% GlobeNewswire
Dec-23	Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change CANF -25.03% CANF GlobeNewswire
Dec-16	Can-Fite Provides Update on Clinical and Financial Status CANF +9.06% GlobeNewswire
Nov-26	Can-Fite's Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference CANF GlobeNewswire
Nov-24	Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference CANF +11.99% GlobeNewswire
Nov-20	Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil CANF -6.95% GlobeNewswire
Nov-18	Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson CANF +5.00% GlobeNewswire
Sep-15	Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson CANF GlobeNewswire
Aug-28	Can-Fite Reports H1 2025 Financial Results and Clinical Update CANF GlobeNewswire
Jul-30	Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone CANF -5.26% GlobeNewswire
Jul-28	Can-Fite Announces Up To $15.0 Million Public Offering CANF -28.43% GlobeNewswire
Jul-28	Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia CANF -28.43% GlobeNewswire
Jun-16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston CANF +6.54% GlobeNewswire
May-05	Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis CANF GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.